Other Events ·
Aptevo to present multispecific platform data at SITC 2026 Annual Meeting
APVOAptevo Therapeutics Inc.
Aptevo Therapeutics announced it will showcase its multispecific platform, specifically a CD40-directed portfolio designed to coordinate innate and adaptive immune activity within the tumor microenvironment, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation is scheduled for November 4–8, 2026, in Phoenix, Arizona. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel multispecific immunotherapies for the treatment of cancer.